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drug and is strongly associated with presence of the human
leukocyte antigen (HLA)-B*5701. Screening for HLA-B*5701
reduces the risk of developing an abacavir hypersensitivity
reaction. The carriage rate of HLA-B*5701 has not been stud-
ied in Georgia before 2009. Objective of the study was to
determine HLA-B*5701 prevalence in HIV-infected patients
in Georgia.
Methods: One hundred and sixty HIV-1 positive patients
attending Georgian Infectious Diseases, AIDS and Clinical
Immunology Research Center in 2009 within the national
treatment and care program were recruited for the study.
None of the patients had previously been treated with
abacavir. Blood samples were collected and screened for
HLA-B*5701 prior to abacavir prescription. Statistical anal-
yses were performed using SAS 9.1. Proportion with exact
95% conﬁdence interval (CI) and median with interquartile
range (IQR) are reported.
Results: Of 160 patients recruited 108 were male (67.5%)
and 42 (32.5%) - female. Median age of subjects was 32 years
(IQR 27—36). Nine patients tested HLA B*5701 positive —
5.6% (95% CI: 2.6—10.4%). Out of these nine patients 7 were
males (male prevalence: 6.5%, [95% CI: 2.6—12.9] %) and 2
females (female prevalence: 4.8% [95% CI: 0.6—16.2%]).
Conclusion: The ﬁrst prospective study of HLA-B*5701
prevalence in Georgia show similar results to the results
of other studies conducted in Caucasians. Abacavir still
remains one of the key drugs of antiretroviral regimens in
Georgia and other resource limited countries. Therefore,
prospective HLA-B*5701 screening should be implemented
in all settings where abacavir is widely used to guide selec-
tion of ART regimens and to reduce the risk of potentially
life threatening hypersensitivity reaction.
doi:10.1016/j.ijid.2010.02.2032
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Background: When hepatotoxicity develops in the course
of treatment with anti-tuberculosis and anti-retroviral
drugs, early improvement is important in order to con-
tinue speciﬁc treatment as early as possible. We aimed
to determine the efﬁcacy, safety and effect on quality of
life of phosphatidyl choline-containing multivitamin in the
management of antiretroviral and anti-tuberculosis hepato-
toxicity.
Methods: This was a randomized, single blinded placebo-
controlled pilot study. Included in the study were subjects
that had been enrolled to access drugs in the ARV pro-
gramme of Jos University Teaching Hospital (JUTH), who
had signed consent to participate in the parent PEPFAR
protocol and have started ARVs or antituberculous drugs.
Subjects received phosphatidyl choline-containing multivi-
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amin (Livolin forte®) or placebo (Vitamin B +Vitamin E as
n Livolin forte). Patients had either been on antitubercu-
ous or antiretroviral medications. Subjects on each arm
ere reviewed fortnightly or earlier if they had worsening
f symptoms. The liver function tests including ALT, AST
mprovements and deteriorations were noted and appro-
riate clinical decisions were taken according to standard
uidelines during the four weeks of each recruitment. The
ata were analysed and displayed in proportions and appro-
riate representations.
Results: Sixteen subjects completed the study. Five and
leven subjects were on placebo and livolin respectively.
he placebo recruitment was stopped after the ﬁfth sub-
ect due to deteriorations in liver function with associated
ncreased mortality in that group. Nine subjects were co-
nfected with Hepatitis B or C infection and one had triple
nfection of all three viruses. The baseline means ALT
or the livolin group and placebo arms were 313.19mM/L
nd 239.76mM/L respectively. There was signiﬁcant decline
f the mean ALT in the livolin group to 49.21mM/L and
8.17mM/L compared to placebo group 227.74mM/L and
29.24mM/L at two and four weeks respectively. While
oint pains reduced from 73.3% through 6.7% to 0% at the
nd of the study period in the Livolin group; the placebo
rm showed a ﬂuctuating course of 33.3%, 83.3% and 16.7%
espectively.
Conclusion: Phosphatidyl choline-containing multivita-
in demonstrated moderate beneﬁts to HIV infected
atients who develop hepatotoxicity to anti-tuberculosis or
ntiretroviral drugs when introduced early in their manage-
ent.
oi:10.1016/j.ijid.2010.02.2033
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Background: Primary drug-resistance in HIV-1, whether in
ajor viral populations or minor populations, is a signiﬁcant
linical and public health concern. Previous studies based on
onventional direct sequencing of virus samples have shown
hat HIV-1 primary drugresistance was insigniﬁcant in Singa-
ore. But it is not clear whether this is also true to the minor
IV-1 populations of the samples because direct sequencing
sually cannot detect resistance mutations in these popula-
ions. We performed this study to determine the prevalence
f primary drug-resistance in minor HIV-1 populations.
Methods: Twenty-four PBMC-associated virus samples
rom 24 newly-diagnosed treatmentnaïve patients were ana-
yzed. PCR products of pol gene that encompass the entire
rotease gene and two-third of the reverse transcriptase
ene were ampliﬁed using an in-house method. The PCR
roducts were then column-puriﬁed for direct sequencing
nd gel-puriﬁed for clonal sequencing. The viral gene cloning
as performed using the TOPO TA cloning kit (Invitrogen).
